

RUSH Institutional Biosafety Committee (IBC)	
Meeting Date	June 24, 2026
Meeting Time	12:00 PM – 1:00 PM
Meeting Type	Virtual via Microsoft Teams
IBC Members Present	1. Amarjit Viridi, Ph.D. (IBC Chair) 2. Ed R. Blazek, Ph.D., SM (NRCM) (BSO) 3. João Mamede, Ph.D. (IBC Member / Recombinant DNA Technologies) 4. Adam Roubitchek, Ed.D. (Non-Affiliated Member) 5. Jennifer Strong (<i>ex officio</i> Non-Voting / Research Compliance) 6. Derrick Swistak (Non-Affiliated Member)
Quorum	Quorum was declared by the Chair. The IBC has nine voting members, and five members are required to conduct business. One member joined late.
Other Individuals in Attendance	1. Christine VanTubbergen, MPH (Program Manager, Office of Research Affairs)
Call to Order	The Chair called the meeting to order at 12:02 PM.
Conflicts of Interest	The Chair reminded all members present to identify any conflicts of interest as each application is reviewed.
Review and Approval of Previous Meeting Minutes	May 27, 2026 Motion: Approve the minutes as circulated. Votes: 4-0-1-0 (for-against-abstain-recuse)

Review of Prior Business		
PI Name & ORA #	Application	Approval Date
Asimakopoulos, Fotios, M.D. 25040806-IBC01	Initial Application	05/28/2026
Romanova, Liudmila, Ph.D. 25011308-IBC01	Initial Application	05/28/2026
Berry-Kravis, Elizabeth, M.D. 24042305-IBC12	Continuing Review 02	06/08/2026
Baranwal, Anmol, M.D. 21070206-IBC25	Continuing Review 05	06/10/2026
Miller, Rachel, Ph.D. 19050702-IBC02	Amendment 01	06/15/2026
Nathan, Sunita, M.D. 19070910-IBC24	Amendment 22	06/16/2026
Berry-Kravis, Elizabeth, M.D. 26020605-IBC02	Amendment 01	06/24/2026

New IBC Applications for Review	
PI Name	Spagnoli, Anna, M.D.
ORA#	17101102-IBC06
Project Overview	III-D-1 & III-D-3 This study will utilize <i>in vitro</i> methodology and a mouse model to investigate the role of Prx1 in bone fracture and repair.
NIH Guidelines Section	III-D-1 & III-D-3
Risk Assessment & Discussion	• Adeno-associated virus (AAV) is an RG-1 agent. • Adeno-virus (Ad5) is an RG-2 agent. • Lentivirus is an RG-2 agent. • A certified biological safety cabinet (BSC) will be utilized.

	- PPE consisting of lab coat, gloves, surgical mask, eye protection, shoe covers, and head covers will be utilized. - Sharps will be disposed of in biohazard sharps waste container.
Training	For nonclinical research requiring IBC oversight, the PI must complete the CITI Initial Biosafety Training course and lab personnel must complete the CITI Basic Biosafety Training course. For research involving human gene transfer, the PI and personnel must complete either the CITI Recombinant Clinical Biosafety Course or the CITI Recombinant Clinical Coordinator course, depending on research activity involvement. At least one individual has current CITI International Air and Transportation Association (IATA) training, if any biohazardous materials will be shipped.
Occupational Health Representative Review (if applicable)	Not applicable.
BSL Assignment	BSL-2
IBC Vote	- A motion was made to provisionally approve this application pending the following conditions be met: - Addition of complete plasmid maps - Clarification of vector capsid and envelope, and whether vector is non-replicative - Correction to Risk Group for adenoviral vector - Correction that sharps be disposed of directly into biohazardous sharps container <u>Votes:</u> 6-0-0-0 Conflicts of Interest: None.

New IBC Applications for Review	
PI Name	Spagnoli, Anna, M.D.
ORA#	20031802-IBC02
Project Overview	III-D-1 & III-D-3 This study will utilize <i>in vitro</i> methodology and a mouse model to investigate the role of IL-36 in osteoarthritis.
NIH Guidelines Section	III-D-1 & III-D-3
Risk Assessment & Discussion	- Adeno-associated virus (AAV) is an RG-1 agent. - Adeno-virus (Ad5) is an RG-2 agent. - Lentivirus is an RG-2 agent. - A biological safety cabinet (BSC) will be utilized. - PPE consisting of lab coat, gloves, surgical mask, eye protection, shoe covers, and head covers will be utilized. - Sharps will be disposed of in biohazard sharps waste container.
Training	For nonclinical research requiring IBC oversight, the PI must complete the CITI Initial Biosafety Training course and lab personnel must complete the CITI Basic Biosafety Training course. For research involving human gene transfer, the PI and personnel must complete either the CITI Recombinant Clinical Biosafety Course or the CITI Recombinant Clinical Coordinator course, depending on research activity involvement. At least one individual has current CITI International Air and Transportation Association (IATA) training, if any biohazardous materials will be shipped.
Occupational Health Representative Review	Not applicable.

(if applicable)	
BSL Assignment	BSL-2
IBC Vote	- A motion was made to provisionally approve this application pending the following conditions be met: - Removal of inaccurate terminology from abstract - Clarification of lentiviral envelope, what AAV will be used, and that Ad5 is non-replicative - Correction to Risk Group - Correction that sharps be disposed of directly into biohazardous sharps container <u>Votes:</u> 6-0-0-0 Conflicts of Interest: None.

New IBC Applications for Review	
PI Name	Miller, Rachel, Ph.D.
ORA#	19050702-IBC04
Project Overview	III-D-1 & III-D-3 This study will utilize a mouse model to investigate the role of Piezo2 in joint damage and pain.
NIH Guidelines Section	III-D-1 & III-D-3
Risk Assessment & Discussion	- Adeno-associated virus (AAV) is an RG-1 agent. - A biological safety cabinet (BSC) will be utilized. - PPE consisting of lab coat, gloves, surgical mask, and eye protection will be utilized.
Training	For nonclinical research requiring IBC oversight, the PI must complete the CITI Initial Biosafety Training course and lab personnel must complete the CITI Basic Biosafety Training course. For research involving human gene transfer, the PI and personnel must complete either the CITI Recombinant Clinical Biosafety Course or the CITI Recombinant Clinical Coordinator course, depending on research activity involvement. At least one individual has current CITI International Air and Transportation Association (IATA) training, if any biohazardous materials will be shipped.
Occupational Health Representative Review (if applicable)	Not applicable.
BSL Assignment	BSL-2
IBC Vote	- A motion was made to approve this application pending the following conditions be met: - Correction to application question regarding use of infectious agents - Correction to Risk Group - Confirmation of staffing <u>Votes:</u> 6-0-0-0 Conflicts of Interest: None.

New IBC Applications for Review	
PI Name	Mamede, João, Ph.D.
ORA#	24041004-IBC01
Project Overview	III-D-1 This study will investigate the mechanisms of neuroinflammation under HIV infection and combination antiretroviral therapies.
NIH Guidelines Section	III-D-1

Risk Assessment & Discussion	• Adeno-associated virus (AAV) is an RG-1 agent. • Human immunodeficiency virus (HIV) is an RG-3 agent. • Herpes simplex virus (HSV-1) is an RG-2 agent. • A biological safety cabinet (BSC) will be utilized. • PPE consisting of lab coat, reusable rear-closing gown, disposable rear-closing gown, gloves, surgical mask, eye protection, head covers, and shoe covers will be utilized.
Training	For nonclinical research requiring IBC oversight, the PI must complete the CITI Initial Biosafety Training course and lab personnel must complete the CITI Basic Biosafety Training course. For research involving human gene transfer, the PI and personnel must complete either the CITI Recombinant Clinical Biosafety Course or the CITI Recombinant Clinical Coordinator course, depending on research activity involvement. At least one individual has current CITI International Air and Transportation Association (IATA) training, if any biohazardous materials will be shipped.
Occupational Health Representative Review (if applicable)	Not applicable.
BSL Assignment	• BSL-2
IBC Vote	• A motion was made to provisionally approve this application pending the following conditions be met: • Completion of biosafety training for all listed personnel • Correction to PI name on Lab Rules • Confirmation on method of liquid disinfection • Confirmation on whether IATA training is required for this study <u>Votes:</u> • 5-0-0-0 Conflicts of Interest: The PI of this study is also a voting member of the IBC. After providing a summary of the application and responding to Committee member questions, but before further discussion and voting commenced, the PI left the meeting.

New Business	Nothing to report.
Review of Incidents	Nothing to report.
Inspections/Ongoing Oversight	Nothing to report.
IBC Training	Nothing to report.
Public Comments	There were no public comments.
Adjournment	The Chair moved to adjourn the meeting at 12:46 PM The next meeting scheduled is for August 26, 2026 at 12:00 PM via Microsoft Teams.